Eptinezumab
Vyepti (eptinezumab) is an antibody pharmaceutical. Eptinezumab was first approved as Vyepti on 2020-02-21. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1 and calcitonin gene-related peptide 2.
Trade Name | Vyepti |
---|---|
Common Name | Eptinezumab |
Indication | |
Drug Class | Monoclonal antibodies: humanized, neural indications |
